AJJ Healthcare Management, a subsidiary of AJJ Medtech Holdings Limited, has entered into a strategic partnership with Suzhou ZOEY Medical Devices to develop and produce hollow fibre haemodialysers in Singapore. This collaboration marks AJJ’s entry into the renal dialysis value chain, offering a cost-competitive alternative to current imported dialysis products, potentially saving patients between 10% and 30%.
The partnership leverages AJJ’s ISO 13485-certified quality infrastructure and OEM management platform, enabling the company to expand into the high-value renal care sector. This move is part of AJJ’s strategic transformation from a trader to a system-driven medical manufacturing and registration platform. The collaboration is expected to address the rising treatment costs in Singapore’s healthcare system without compromising quality.
Singapore’s haemodialysis market, serving approximately 7,800 patients, presents a significant opportunity for AJJ. The recurring nature of dialysis treatments ensures a stable demand, providing a solid foundation for long-term revenue. The partnership also promises to bring solutions to market 12 to 18 months faster than conventional approaches, thanks to AJJ’s integrated OEM framework.
The collaboration is built on strong quality standards, with both parties maintaining ISO 13485-certified systems. AJJ retains audit rights and will benefit from supply arrangements that provide access to future product innovations. The financial impact is expected to be minimal for FY2025, with significant contributions anticipated from the second half of 2026, following successful Health Sciences Authority approval.
